Indication
For the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).
Medicine details
- Medicine name:
- secukinumab (Cosentyx)
- SMC ID:
- SMC2308
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Full
- Publication due date:
- 11 January 2021
- Patient group submission deadline:
- 02 November 2020